Stoke Therapeutics Plunges 12.75% on CEO Departure, Q4 Loss

On April 10, 2025, Stoke Therapeutics experienced a significant drop of 12.75% in pre-market trading, reflecting a notable shift in investor sentiment towards the company.

Stoke Therapeutics recently reported a loss for the fourth quarter but managed to exceed revenue estimates, which could have contributed to the recent market reaction. Additionally, the company announced that its CEO, Edward Kaye, will be stepping down, a move that often introduces uncertainty and can impact stock performance.

Despite the recent decline, analysts maintain a strong buy rating for Stoke Therapeutics, with an average price target suggesting a substantial upside from current levels. This positive outlook from analysts may provide some support for the stock in the coming days, as investors weigh the potential for future growth against current market volatility.